Name: Organ Preservation and Survival in Head and Neck Cancer
Start: 2026-03-06
End: 2026-03-06
Location: David Rubenstein Forum at the University of Chicago

OVERVIEW

Organ Preservation and Survival in Head and Neck Cancer is organized by Meeting Achievements, LLC and will be held on Mar 06, 2026 at David Rubenstein Forum at the University of Chicago, Chicago, Illinois, United States of America.

Description:
Join top experts for an engaging, case-driven symposium designed to sharpen your clinical edge across the full spectrum of head and neck malignancies. Dive into the latest in organ-preserving strategies for laryngeal, oropharyngeal, and oral cavity cancers, plus emerging treatments for rare tumors like salivary gland, thyroid, and cutaneous cancers.

Explore breakthrough topics including chemoimmunotherapy, novel surgical and reconstructive techniques, precision radiation, AI, ctDNA, and adaptive treatment planning. Walk away with practical insights you can apply immediately to improve outcomes, reduce toxicity, and lead multidisciplinary care with confidence.

Don’t miss this opportunity to recharge your expertise, rethink your approach, and connect with innovators shaping the future of head and neck cancer care.

Learning Objectives:
After this activity, participants will be able to:

Recognize key diagnostic and treatment considerations for rare non-squamous head and neck cancers to support multidisciplinary care planning;
Describe emerging technologies used in the diagnosis and treatment of head and neck malignancies to enhance precision and reduce treatment-related toxicity;
Summarize key therapeutic and diagnostic developments in head and neck cancer over the past two decades to contextualize current organ preservation strategies;
Interpret current biological and therapeutic findings to optimize multimodal treatment planning for advanced oral cavity cancer;
Compare emerging organ-preserving strategies for laryngeal cancer based on efficacy and functional outcomes to guide personalized treatment planning;
Evaluate de-escalation strategies and response-adaptive therapies for HPV-positive oropharyngeal cancer to reduce treatment-related morbidity without compromising survival.